Focused on selective acquisitions of high-quality companies in strategic industrial sectorsMILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that, with respect to its biotechnology platform, Genenta has been and continues to be actively engaged with DC Advisory to explore potential collaboration opportuni ...

Core Viewpoint - Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on strategic industrial consolidation in biotech, defense, aerospace, and Italian national-security-related technologies [1] Company Developments - Pierluigi Paracchi, CEO of the company, has been appointed to the Board of Guarantors of the Italian Academy for Advanced Studies in America, enhancing the company's connection to cultural and academic institutions [1][2] - The Board of Guarantors consists of twelve members, with six appointed by the Italian Government and six by Columbia University, playing a crucial role in supporting the Academy's activities [2][3] Strategic Focus - Saentra Forge aims to consolidate specialized companies in sectors regulated by Italian national security, including cybersecurity, defense, aerospace, and biotechnology/biosecurity [4] - The company emphasizes the importance of connecting science, industry, and international collaboration for long-term competitiveness, aligning with the Academy's mission [4]

Core Insights - Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on strategic industrial consolidation in biotech, defense, aerospace, and Italian national-security-related technologies [1][4] - Pierluigi Paracchi, CEO of the company, has been appointed to the Board of Guarantors of the Italian Academy for Advanced Studies in America, enhancing the company's ties with academic institutions [2][4] Company Overview - Genenta Science, soon to be known as Saentra Forge, will operate as a next-generation strategic consolidator targeting privately held specialized companies in sectors regulated by Italian national security, including cybersecurity, defense, aerospace, and biotechnology/biosecurity [1][4] Board of Guarantors - The Board of Guarantors consists of twelve members, with six appointed by the Italian Government and six by Columbia University, playing a crucial role in supporting the Academy's activities and maintaining academic excellence [2][3] - The Italian Academy for Advanced Studies in America, founded in 1991, promotes dialogue and collaboration among scholars and artists, fostering Italian culture and intellectual exchange [3]

Core Viewpoint - Genenta Science SPA (NASDAQ:GNTA) is transitioning from a focus on biotech, particularly cancer treatments, to a new strategy centered on defense and national security, with plans to change its name to Saentra Forge [1][4]. Group 1: Business Strategy Shift - The company announced a major shift in its business strategy on January 27, moving away from biotech programs to focus on acquiring private Italian businesses in the national security sector [1][2]. - Genenta aims to target profitable businesses that generate approximately €5 million in annual EBITDA and has begun scouting for these acquisition targets [2]. Group 2: Acquisition Plans - Genenta has reached an agreement to potentially acquire ATC, a manufacturer of tactical rifles and special-forces weapon systems, contingent on meeting certain performance milestones [2]. - ATC is projected to generate €2.0 million in EBITDA in 2026, with expectations to double this amount in 2027 [3]. Group 3: Continued Biotech Commitment - Despite the pivot to defense, Genenta will maintain its biotech programs through partnerships, indicating a dual focus moving forward [3]. Group 4: Company Background - Founded in 2014 and headquartered in Milan, Italy, Genenta's lead drug candidate in the biotech space is Temferon, aimed at treating solid tumor indications [4]. - The decision to shift to defense is described as a response to changing market dynamics [4].

Core Insights - Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on biotech, defense, aerospace, and national-security technologies [1] - The company appointed Paolo Salvato to the Board of Directors of ATC, marking its entry into defense technology manufacturing [1] - Genenta is evaluating acquisition opportunities in regulated national-security sectors to build a strategic industrial consolidator [3] Company Developments - Paolo Salvato has over two decades of experience in defense industrial operations, previously serving as CEO of Fiocchi Munizioni and Thales Italia [2] - The company aims to acquire profitable, majority-controlled, privately-held industrial businesses, leveraging its Nasdaq listing for financial flexibility [4][6] - Genenta's biotech program has reached clinical maturity, with a focus on strategic partnerships to advance development and minimize risk [6] Clinical and Scientific Progress - Nature Medicine has accepted a manuscript detailing clinical findings from Genenta's Glioblastoma Multiforme trial, expected to be published soon [5] - The publication is seen as a validation of the company's scientific and clinical efforts [5] Strategic Vision - The transformation reflects a response to evolving market dynamics, with an emphasis on the intersection of advanced biotechnology and defense technologies [6] - The company is focused on acquiring businesses with positive EBITDA and integrating them into a transparent, publicly listed platform for long-term value creation [6]

Core Viewpoint - Genenta Science S.p.A is transforming into Saentra Forge S.p.A, focusing on acquiring privately held businesses in national-security regulated sectors under Italian Golden Power legislation, targeting companies with up to €5 million in EBITDA [1][10] Group 1: Strategic Transformation - The company aims to become a next-generation strategic industrial consolidator, pursuing a value-creation strategy by acquiring targets at private-market valuations and integrating them under Saentra Forge [2] - The first acquisition target is ATC, a defense-sector company specializing in high-precision manufacturing of tactical rifles and special-forces weapon systems [3] Group 2: Financial Projections and Funding - Genenta plans to fund ATC with a total of €5.1 million through performance-driven tranches, aiming for a controlling position upon achieving defined performance milestones [3] - ATC projects revenues of approximately €4.0 million in 2026, increasing to around €9.0 million by 2027, with an expected EBITDA of more than €2.0 million in 2026, potentially doubling in 2027 [3] Group 3: Governance and Strategic Partnerships - The Praexidia Foundation has joined as a strategic long-term shareholder, enhancing the company's governance framework and supporting regulatory coherence [4][5] - A shareholders' agreement has been established to ensure consultation rights on significant corporate transactions and a renewable five-year lock-up, reinforcing long-term alignment and effective control [5] Group 4: Biotech and Cash Position - The company has reached key clinical milestones in its cell therapy platform, engaging DC Advisory as its exclusive financial advisor for partnership initiatives [6] - Expected cash, cash equivalents, and marketable securities at December 31, 2025, are approximately $33 million, up from $17.7 million at June 30, 2025, primarily due to a registered direct offering [9]

Core Viewpoint - Genenta Science provides an update on the ownership position of its CEO and Co-Founder, Pierluigi Paracchi, highlighting his significant investment in the company through open-market purchases of American Depositary Shares (ADSs) [1][2]. Company Ownership - Pierluigi Paracchi has acquired a total of 30,000 ADSs through open-market purchases, with no reported sales [2]. - As of December 19, 2025, Mr. Paracchi owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of Genenta's outstanding share capital [3]. Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing hematopoietic stem cell therapies for solid tumor cancers [4]. - The company's lead product candidate, Temferon™, aims to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing immune responses [4]. - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients, indicating potential for reprogramming the tumor microenvironment and inducing T cell responses [4]. - A Phase 1/2a study for metastatic Renal Cell Carcinoma has been initiated, which will explore combinations with immune checkpoint inhibitors [4]. - Genenta's therapies are designed as one-time monotherapies but may also enhance the efficacy of other approved treatments when used in combination [4].

Core Insights - Genenta Science has provided an update on its TEM-GBM study for newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter, reporting that 25 patients have been treated with Temferon as of November 21, 2025 [1][2] Group 1: Clinical Study Results - Key survival metrics for TEM-GBM patients show that 44% of patients have reached 18-month survival, an increase from 38% reported in April 2025 [7] - The two-year survival rate remains at 29%, and the median overall survival is consistent at 17 months, compared to historical cohorts of uMGMT patients treated with standard care, which typically show a two-year survival rate of approximately 14% and median overall survival of 13-15 months [7] - The study includes a patient who has reached three years of survival following Temferon administration, marking a significant milestone in the study [7] Group 2: Mechanism and Observations - The GBM study provides early observations on Temferon's behavior within the tumor microenvironment, indicating that bone-marrow-derived myeloid cells can deliver immunotherapeutic payloads at the tumor site, aligning with the platform's intended design [3] - These preliminary findings are exploratory and will inform the broader development of Temferon, including potential combination approaches and the evolution of the underlying cell-based delivery technology [3] Group 3: Financial Position - Following a registered direct offering on October 27, the company reported approximately $30 million in cash and short-term investments as of November 1, 2025 [4] Group 4: Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for various solid tumor cancers, with Temferon as its first-in-class product candidate [5] - The company has completed a Phase 1 trial for newly diagnosed GBM patients with an unmethylated MGMT gene promoter, suggesting potential reprogramming of the tumor microenvironment and induction of T cell responses [5] - Genenta has also initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will include combinations with immune checkpoint inhibitors [5]

Core Insights - Several biotech and healthcare stocks experienced significant after-hours trading gains due to clinical updates, strategic deals, and regulatory milestones [1] Company Summaries - **Genenta Science S.p.A. (GNTA)**: Shares closed at $2.40, down 27.71% during regular trading, but rebounded to $2.45, up 2.08% in after-hours. The volatility was driven by a $15 million registered direct offering and a strategic collaboration announcement [2] - **EDAP TMS S.A. (EDAP)**: Closed at $1.81, down 22.58%, but rose 8.29% to $1.96 in after-hours trading. The recovery appears technical, with no new news, and is supported by upcoming investor meetings at the UBS Global Healthcare Conference [3] - **BridgeBio Pharma Inc. (BBIO)**: Ended regular trading at $64.50, up 1.48%, and climbed 6.71% to $68.83 after hours. The increase reflects anticipation for Phase 3 CALIBRATE trial results for ADH1, with topline data expected on October 29 [4] - **OrthoPediatrics Corp. (KIDS)**: Closed at $16.91, down 0.29%, but surged 6.45% to $18.00 after releasing Q3 financial results, reporting a GAAP loss per share of $(0.50) despite 12% revenue growth [5][6] - The company raised its full-year 2025 revenue guidance to $233.5 million to $234.5 million, indicating projected growth of 14% to 15% compared to the prior year [7] - **Modular Medical Inc. (MODD)**: Dipped 1.30% to $0.5392 but rallied 5.38% to $0.5682 after hours following the successful completion of its Stage 1 ISO 13485:2016 audit, a key step toward CE Mark certification [8] - **Vivani Medical Inc. (VANI)**: Rose 3.09% to $1.67 and added 3.65% to $1.7310 after closing a $15.7 million capital raise, which included a registered direct offering and private placement, indicating insider confidence [9] - **Amarin Corp. plc (AMRN)**: Slipped 1.56% to $18.94 but rebounded 5.07% to $19.90 after the FDA revised fenofibrate drug labeling, which may favor Amarin's Vascepa in the lipid management space [10]

Core Viewpoint - Genenta Science (NASDAQ: GNTA) has received a "Buy" rating following a significant stock increase of 90% on Friday due to positive news [2]. Company Overview - Genenta Science is a pharmaceutical company that has recently gained attention in the biotech sector [2]. - The company is part of a broader analysis service that includes a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2]. Market Context - The stock market reaction indicates strong investor interest and confidence in Genenta Science, reflecting potential growth opportunities in the biotech industry [2].